A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia. That’s a potential game changer for the more than 6 million Americans diagnosed each year and the 100,000 who die from the memory-robbing disease annually.

A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and similar GLP-1 agonists, but without muscles loss as a potential side-effect. This is the conclusion of a new study by an international team of researchers led from the biotech firm Atrogi AB.

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.